These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24460357)

  • 1. Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
    Vo LT; Thuan TB; Thu DM; Uyen NQ; Ha NT; To TV
    Asian Pac J Cancer Prev; 2013; 14(12):7713-8. PubMed ID: 24460357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
    Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
    Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
    Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
    Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer.
    Vu TL; Nguyen TT; Doan VTH; Vo LTT
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1887-1893. PubMed ID: 30049201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer.
    Pradjatmo H; Dasuki D; Anwar M; Mubarika S; Harijadi
    Asian Pac J Cancer Prev; 2014; 15(21):9479-85. PubMed ID: 25422243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
    Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
    Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
    Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.
    Chen C; Zhu Y; Zhang H; Xiao L
    Gynecol Obstet Invest; 2024; 89(5):363-375. PubMed ID: 38615670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
    Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
    Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methylation of selected tumor-supressor genes in benign and malignant ovarian tumors].
    Cul'bová M; Lasabová Z; Stanclová A; Tilandyová P; Zúbor P; Fiolka R; Danko J; Visnovský J
    Ceska Gynekol; 2011 Sep; 76(4):274-9. PubMed ID: 22026068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.